

6 March 2015

Suite 1, 1233 High Street  
Armadale VIC 3142

## **Imugene to Present at 27<sup>th</sup> Annual Roth Conference**

---

**Melbourne, Australia, 6 March 2015:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, has been invited to present at the 27<sup>th</sup> Annual Roth Conference. Managing Director Mr. Charles Walker will present at 3:00 PM PT, 10 March at the Ritz Carlton in Laguna Niguel, California.

The annual Roth Conference focuses on small and mid-cap growth companies over three days with in excess of 1,000 investors attending. Roth is an investment banking firm dedicated to the small-cap public market. Roth's headquarters is located at Newport Beach, CA and has offices in Boston, Chicago, Larkspur, Los Angeles, New York, San Diego and Hong Kong.

A live webcast in addition to the presentation materials will be available for review on the Investor Relations section of the Company's website at [www.imugene.com](http://www.imugene.com).

### **About Imugene**

Imugene (ASX: IMU) is an immuno-oncology biopharmaceutical company developing HER2 positive gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.

### **Contact**

#### **Charles Walker**

Managing Director  
[cwalker@imugene.com](mailto:cwalker@imugene.com)  
Tel: +61 (0) 4 5044 6990

#### **Rudi Michelson**

Monsoon Communications  
Ph: +61 (0) 3 9620 3333

#### **Stephanie Carrington**

Integrated Corporate Relations (ICR)  
[stephanie.carrington@icrinc.com](mailto:stephanie.carrington@icrinc.com)  
Ph: 646-277-1282